HIVEP3 and osteoporosis: The absence of SHN3 effectively restores bone remodeling processes, mitigating bone loss associated with osteoporosis, facilitating fracture repair, and treating OI.[8, 9, 10, 11, 12, 22] To further investigate whether VDC‐mediated silencing of SHN3 offers therapeutic benefits for these osteolytic diseases, we assessed the osteogenic effects of VDC in vivo using ovariectomized (OVX), fractured, and OI mouse models.